Novo Nordisk to build massive haemophilia facility in Denmark
The Danish pharmaceutical giant Novo Nordisk has announced it will invest 1.5 billion kroner in a new haemophilia treatment manufacturing facility in Kalundborg.
The new 7,500 sqm facility will create an estimated 100 new jobs in Kalundborg, where Novo Nordisk already employs more than 2,800 people.
“The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark,” explained Henrik Wulff, the executive vice president of the product supply division at Novo Nordisk.
“This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly-skilled employees.”
The investment comes as part of an offensive investment strategy that the company unveiled recently.
Just last month, the company revealed it had opened a new manufacturing facility in Russia – dedicated to the treatment of diabetes – in the city of Kaluga, located about 150 kilometres southwest of Moscow.
Last week, Novo Nordisk revealed financial results for the first quarter of 2015 that showed a turnover of 25.2 billion kroner and profit of 13.9 billion kroner.